Clinicians should take into account the way IOP varies over the course of 24 hours depending on the glaucoma treatment used, according to the authors of a new literature review.
Clinicians should take into account the way IOP varies over the course of 24 hours depending on the glaucoma treatment used, according to the authors of a new literature review.
“We need to check pressures more often than once, outside the ‘office hours’ and if possible at night when patients are asleep,” wrote Anastasios G.P. Konstas, from 1st University Department of Ophthalmology, Aristotle University of Thessaloniki, Greece, and colleagues. They published their finding in Advances in Therapy.
Related: More about the gel stent leading to 40% reduction in IOP
While randomized controlled trials show that reducing IOP reduces the rate of visual loss in most glaucoma patients, researchers have too often assumed that a single daytime measurement provides an adequate understanding of whether a patient’s IOP is under control. Most clinicians only measure IOP during patient visits about every three months.
A single IOP measurement only indicates what is happening for 1 out of 1439 minutes per day, they noted. Other trials have shown that the efficacy of a given therapy can vary over the course of this time. As a consequence, clinicians may not be making the best choice about whether to use surgery, laser, or medication.
Recent: How vital is signal strength when analyzing OCT scans?
Twenty-four-hour monitoring would reveal the true peak IOP and the level at which damage occurs, allowing an optimal level to be set for each patient, the researchers wrote. However, such constant monitoring is not yet possible for most patients.
The researchers analysed randomised controlled trials to see how IOP measurements varied over 24 hours with each therapy in hope of providing information clinicians can use to guide their treatment plans.
Normal fluctuations
IOP normally fluctuates throughout the day by around 4-6 mm HG, Konstas and colleagues found. In patients with ocular hypertension (OHT), the 24-hour fluctuation usually averages 6-8 mm Hg, but sometimes reaches 15 mm Hg. In glaucoma patients the 24-hour fluctuation usually ranges from 6-15 mm HG, but can reach as high as 40 mm Hg, they reported.
In most studies, IOP in untreated glaucoma is highest between 6 a.m. and noon; the authors noted the highest IOP in their own patients at 10 a.m. This time can also vary with the patient and type of glaucoma, they noted.
Recent: How viscoelastic injection may improve microstent efficacy
For example, one study found that 45% of patients with exfoliation glaucoma (XFG) and 22.5% of patients with primary open-angle glaucoma (POAG), reach peak IOP outside office hours.
The patient’s position can affect IOP as well; in general, a patient’s IOP is lower when sitting than when lying supine, the researchers reported.
Among the findings from various medication studies they identified:
More Glaucoma: Visit the glaucoma homepage
How laser trabeculoplasty affects IOP
Less is known about the relationship of laser trabeculoplasty to circadian characteristics of IOP. Still, a handful of studies have produced interesting results, among them:
Related: Better alternatives to standalone prostaglandin analog therapy
Related news: How MIGS procedure surpasses a trabeculectomy
IOP fluctuations following trabeculectomy
A variety of studies have also examined 24-hour fluctuations in IOP following trabeculectomy. Some of the findings:
Learn more: Impressive IOP results from second-generation microinvasive surgery
The authors concluded by describing a novel wireless telemetry sensor for monitoring IOP in POAG, consisting of a silicon contact lens with a micro-electromechanical system (Sensimed AG). They noted a recent study finding that the device did not correlate Goldmann IOP readings, and did not detect differences in IOP between sitting and supine positions.
They called for new technology to make continuous monitoring feasible for everyone whose IOP is being treated.
Recent glaucoma news: How a novel device reliably measures iridocorneal angles